^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Ninlaro (ixazomib) (Proteasome inhibitor) + pomalidomide (TNFα inhibitor, IL-6 inhibitor, NK cell stimulant, IL-10 stimulant, IL-1β inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
...the NCCN panel has included ixazomib/pomalidomide/dexamethasone as a treatment option for patients with relapsed/refractory MM... the NCCN Panel has included ixazomib/pomalidomide/dexamethasone as a preferred regimen option for previously treated MM.
Secondary therapy:
dexamethasone
